Are psychedelics effective under anesthesia?: Boris Heifets (Stanford pt 2)
Aug 17, 2023
auto_awesome
Boris Heifets, an assistant professor at Stanford's School of Medicine, discusses his research on the effects of ketamine on patients with depression under anesthesia. He also explores the impact of different environments on the effects of psilocybin in mice and reflects on the hype cycle of psychedelics.
Dissociation and acute subjective experience may not be the primary factors contributing to the therapeutic effects of ketamine on depressive symptoms.
For psilocybin, the specific environment may have less impact on the psychedelic experience compared to other factors.
Deep dives
Ketamine Study on Anesthetized Patients with Depression
The study aimed to evaluate the effects of ketamine on anesthetized patients with depression. The researchers wanted to determine the importance of dissociation and the acute subjective experience of ketamine on the improvement of depressive symptoms. The study involved administering ketamine or a placebo to patients under general anesthesia, and the outcomes were assessed based on depression scores before and after the infusion. Surprisingly, both the ketamine and placebo groups showed a massive treatment effect of similar magnitude in terms of symptom improvement. This suggests that dissociation and acute subjective experience may not be the primary factors contributing to the therapeutic effects of ketamine.
The Study on Set and Setting using Mice
The study aimed to explore the influence of set and setting on the effects of psilocybin in mice. Set and setting refer to the psychological and environmental factors that can influence the psychedelic experience. In this experiment, mice were given either psilocybin or a control solution and were placed in either their familiar environment or a novel environment. The researchers expected to observe significant differences in brain activity depending on the combination of drug and environment. However, they found that there was minimal interaction between the two factors. While the environment had a notable effect on brain activity and psilocybin had its own effects, the interaction between the two was limited. This suggests that for psilocybin, the specific environment may have less impact on the psychedelic experience compared to other factors.
Skepticism and the Therapeutic Effects of Psychedelics
The researcher expressed a belief in the profound therapeutic potential of psychedelics but also expressed skepticism about how these effects are captured within the medical framework. While acknowledging the importance of medicalization for regulatory purposes, the researcher emphasized the broader aspects of well-being, creativity, and personal experiences that may not be easily quantified or explained by medical definitions. The researcher highlighted the need for rigorous research, proper controls, and a comprehensive approach to understanding the therapeutic value of psychedelics beyond traditional psychiatric paradigms.
Future Focus: Exploring States of Consciousness
The researcher's next focus is on exploring states of consciousness and inducing non-drug-induced social and pathogenic states. The goal is to map out how to achieve these states through techniques such as brain stimulation or novel drugs. The aim is to understand and facilitate experiences that have rarely been explored in human history, embracing the potential for personal growth and exploration. The researcher anticipates that this area of study holds significant promise but acknowledges that it will take time to fully uncover and harness the transformative potential of these states.
Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body.
This is part 2 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We continue with Boris Heifets.
Boris Heifets, an assistant professor at Stanford's School of Medicine. Boris leads the Heifets Lab, which is dedicated to understanding and improving on powerful, rapid-acting therapies for psychiatric disease, such as ketamine, MDMA and psilocybin. Boris is an anesthesiologist and neurologist, a combination that uniquely positions him to design a research study evaluating the effect of ketamine on patients under anesthesia with depression.